Nilutamide (Nilandron)

General information

Class/mechanism: Antiandrogen, nonsteroidal. Nilutamide competitively inhibits the effects of testosterone by interacting with the androgen receptor.^[1]^[2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is used

Prostate cancer

Patient drug information

History of changes in FDA indication

1996-09-19: Initial approval in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate. (Based on International Anandron Study)

History of changes in EMA indication

1986-07-02: EURD

Also known as

Brand names: Anandron, Nilandron, Zandron

References

[insert-1] 1.0 ^1.1 Nilutamide (Nilandron) package insert

[2] Nilutamide (Nilandron) package insert (locally hosted backup)

[3] Nilutamide (Nilandron) patient drug information (Chemocare)

[4] Nilutamide (Nilandron) patient drug information (UpToDate)

[1]

[2]

[3]

[4]